Please ensure Javascript is enabled for purposes of website accessibility

Why Glaukos Corp. Is Skyrocketing Today

By Brian Feroldi - May 4, 2016 at 1:01PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

An impressive earnings report filled with good news has traders bidding up shares on Wednesday.

IMAGE SOURCE: PIXARC ON PIXABAY.

What: Shares of Glaukos Corp. (GKOS -3.71%), a medical device company primarily focused on creating products that treat glaucoma, soared more than higher 26% as of 11:15 a.m. EST Wednesday after the company produced a first quarter earnings report that impressed investors.

So what: Glaukos reported net sales of $23.1 million during the period, which was up a strong 57% when compared to the first quarter of last year.

Gross margins also ticked up by 500 basis points to 86% and the company produced a net income of $897,000 for the quarter, or $0.03. That was a huge improvement from the $0.40 loss that it recorded in the year ago period and was far better than the $0.15 loss that Wall Street had expected.

The stronger-than-expected first-quarter results gave management enough confidence for them to raise full-year sales guidance to a range of $100 million to $102 million. That's a sizable increase from their prior range of $90 million to $93 million and the new range compares quite favorably to the $92 million that analysts were expecting.

Now what: Glacukos is on a roll as this is the third quarter in a row that the company has blown passed Wall Streets profit estimates.

Thomas Burns, Glaukos CEO, had this to say about the company's quarterly performance:

Glaukos is off to an exceptional start in 2016 with solid first quarter performance driven by the continuing success of our flagship micro-scale glaucoma device, the iStent Trabecular Micro-Bypass.

On the call, Burns pointed out their early efforts to secure reimbursement for the iStent and are paying huge dividends as the system is now fully reimbursed by Medicare and the majority of private payers. During the quarter, the company signed on Humana as a new insurance provider, which adds almost 10 million new covered lives to their patient pool. The company estimates that 90% of Americans with private insurance now have reimbursement access to the iStent.

The picture is also looking bright in abroad markets as Glaukos recently establish a commercial presence in Australia and Canada and the company has launched the iStent system for sale.

The company is currently working to bring abroad markets online in the near term as the iStent is approved for sale in several countries like Chile, Mexico, and Japan. However, the company is holding back on launching until they can establish reimbursement in those markets. 

All in all, it looks like Glaukos had a wonderful quarter and the company looks well positioned for strong growth in the years ahead. With so much good news baked into this report, it's easy to see why the market is bidding up shares on Wednesday.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Glaukos Corporation Stock Quote
Glaukos Corporation
GKOS
$45.88 (-3.71%) $-1.77
Humana Inc. Stock Quote
Humana Inc.
HUM
$464.39 (0.00%) $0.00

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
332%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/28/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.